UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2020.
Commission File Number001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrant’s name into English)
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form 20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
On February 26, 2020, Summit Therapeutics plc (the “Company”) announced that it appointed Robert W. Duggan as Executive Chairman of the Board of Directors of the Company (the “Board”) with immediate effect. Glyn Edwards will continue as Executive Director and Chief Executive Officer of the Company.
This Report on Form6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on FormF-3 (FileNo. 333-232074).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SUMMIT THERAPEUTICS PLC | ||||
Date: February 26, 2020 | By: | /s/ Glyn Edwards | ||
Glyn Edwards Chief Executive Officer |